Jardiance
- Health
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction
Ingelheim, Germany: – The positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in…
Read More » - United States
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Ingelheim, Germany & Indianapolis, United States: – In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total…
Read More »